Since FDA approval, anti‐VEGF therapy is commonly utilized in ovarian cancer with its therapeutic benefit thought to arise not only from disrupted tumor angiogenesis but also disrupted immune evasion. Here, VEGFA is linked to ovarian carcinoma.